Company

Vaccinex, Inc.

Headquarters: Rochester, NY, United States

Employees: 39

CEO: Dr. Maurice Zauderer Ph.D.

NASDAQ: VCNX +0.56%

Market Cap

$9.0 Million

USD as of Jan. 1, 2024

Market Cap History

Vaccinex, Inc. market capitalization over time

Evolution of Vaccinex, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Vaccinex, Inc.

Detailed Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Vaccinex, Inc. has the following listings and related stock indices.


Stock: NASDAQ: VCNX wb_incandescent

Details

Headquarters:

1895 Mount Hope Avenue

Rochester, NY 14620

United States

Phone: 585 271 2700

Fax: 585 271 2765